Young drug injectors who undergo opioid agonist maintenance therapy using buprenorphine or methadone have a lower likelihood of becoming infected with hepatitis C virus (HCV) than those who continue injecting or use other types of substance use treatment, according to a study published in the October 27 edition of JAMA Internal Medicine.
29 October 2014 | HIVandhepatitis.com
Many women addicted to drugs in Georgia are unable to access harm-reduction programmes because of stigma and discrimination, including from health professionals.
17 October 2014 | The Lancet
The concept note delivered on 8 September for Russia's last HIV grant from the Global Fund was a perfect illustration of the conundrum facing a growing number of Eastern European/Central Asian countries: how to do more with less to fight a widening HIV epidemic. As more countries from the region 'graduate' from Global Fund eligibility due to their income classification, the funds that they could once count on to support prevention, harm reduction and other programs targeting vulnerable populations are disappearing. And there is little evidence that most national budgets are prepared or able to fill the vacuum.
25 September 2014 | Aidspan
Activists fear that due to new ceilings on the size of their grants from the Global Fund, which has been the main source of funding for harm reduction in the absence of government funds, the number of infections could drive higher.
25 September 2014 | Global Fund Observer
So foil is now legal in the UK (since September 5th), needle programmes across the country are now (hopefully) stocking it and offering it as a possible tool for change or early engagement route for people who smoke rather than inject their drug of choice. So here's a bit of advice for those workers giving it out.
09 September 2014 | Injecting Advice
On 3 September, the Office for National Statistics released Deaths related to drug poisoning in England and Wales, 2013. The data relates to deaths registered in 2013 and shows a sharp rise in deaths as a consequence of drug misuse in England and Wales.In 2013, 1,957 drug misuse deaths were registered, up 20 per cent on the figure for 2012 (1,636).
04 September 2014 | DrugScope (press release)
Health workers in Cape Town have warned of a possible increase in drug overdoses and the spread of infectious diseases, including HIV, if the use of needles to inject drugs increases.
This comes as health workers have noticed drug users turning away from smoking towards injecting. In response, the TB/HIV Care Association (THCA) in Observatory are preparing to educate needle using drug users on the safe use of needles. Whereas once hardcore addicts chose to smoke their 'unga' on tinfoil and people who “spiked” the drug were shunned and looked down upon, this is no longer the rule.
02 September 2014 | Groundup
People walking past the pharmacy where volunteers chat with Olesya — an intravenous drug user with HIV — glare at the young woman, quickening their pace as they go. Others, many of them also young women, stop to accept the clean clean syringes, HIV tests and pregnancy tests being handed out as part of an outreach program to do the things that many specialists say authorities are not: acknowledge the fact that a full-blown HIV epidemic is becoming more and more of a reality each day.
20 August 2014 | The Moscow Times
Sovaldi, approved by the Food and Drug Administration (FDA) last year for the treatment of chronic hepatitis C (HCV), has a success rate better than 90 percent, and is ideal for use in opioid treatment programs (OTPs), yet payers are balking at covering it for patients who have a history of a substance use disorder (SUD), ADAW has learned.
14 August 2014 | Alcohol & Drug Abuse Weekly
“Maximizing the benefits of ART for key populations” grew out of discussions between the Key Affected Populations and Treatment as Prevention Working Groups of the International AIDS Society. The two groups agreed that given the rapidly changing treatment and prevention landscape in HIV, there was a need to consider a range of issues affecting treatment access, prevention choices, and the implications of new guidelines for key populations.
24 July 2014 | International AIDS Society